Clinical trial
A Prospective, Multicenter, Phase II Study of Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of Local-stage Mucosa Associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma
NCT06583837 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Phase II Study of Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of Local-stage Mucosa Associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- September 10, 2024
- Completion date
- September 30, 2027
- Enrollment
- 50 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.